{"disease":{"id":"morphea","name":"Morphea","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":3,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"aminobenzoic-acid","indication_name":"Morphea","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aminobenzoate Potassium","generic_name":"aminobenzoic acid","company_name":"","drug_phase":"unknown","molecular_target":"Carbonic anhydrase 2","drug_class":"Vitamin B Complex Member","quality_score":null,"revenue":null,"mechanism":"Aminobenzoate Potassium works by inhibiting the enzyme carbonic anhydrase 2, which plays a crucial role in maintaining the pH balance in cells."},{"drug_id":"benzoic-acid","indication_name":"Morphea","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Benzeneformic Acid","generic_name":"benzoic acid","company_name":"","drug_phase":"marketed","molecular_target":"Nicotinate phosphoribosyltransferase","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"orthocaine","indication_name":"Morphea","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"orthocaine","company_name":"","drug_phase":"unknown","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03630198","title":"Pain Outcomes Following Intralesional Corticosteroid Injections","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":31,"lead_sponsor_name":"Vanderbilt University Medical Center","has_results":true},{"nct_id":"NCT07311070","title":"Treatment of Basal Cell Carcinoma (BCC) of the Skin, of the Morpheiform, Infiltrative, and Noduloulcerative Types in Inoperable Patients and Not Suitable for Radiotherapy Using Formulated Methylene Blue","phase":"PHASE3","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":20,"lead_sponsor_name":"Daryoush Hamidi Alamdari, PhD","has_results":false},{"nct_id":"NCT04954573","title":"Study on the Treatment With Water-filtered Infrared-A (wIRA) Radiation in Patients With Morphea and Sclerotic Graft-versus-host Disease","phase":"NA","overall_status":"TERMINATED","enrollment_count":11,"lead_sponsor_name":"Medical University of Graz","has_results":false},{"nct_id":"NCT03351114","title":"Pilot Study Evaluating the Efficacy of a Topical PDE4 Inhibitor for Morphea","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":8,"lead_sponsor_name":"Duke University","has_results":true},{"nct_id":"NCT04752397","title":"The Influence of Extracorporeal Photopheresis on Skin Sclerosis","phase":"","overall_status":"COMPLETED","enrollment_count":6,"lead_sponsor_name":"Charite University, Berlin, Germany","has_results":false},{"nct_id":"NCT03740724","title":"A Study of FCX-013 Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma (Morphea)","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"Castle Creek Biosciences, LLC.","has_results":true},{"nct_id":"NCT04656704","title":"Hyaluronidase in Treating Oral Microstomia in Patients With Sclerosing Skin Disease","phase":"EARLY_PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT03679845","title":"Study to Assess Sarilumab in Halting Progression of Morphea","phase":"PHASE1, PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false}],"total":8},"guidelines":[],"source":"Drug Landscape verified database"}